Find Academic Supervisors

Mary Beth GrahamView profile

Professor

• Infectious Disease
• HIV Infection
• Infections in Immunocompromised Patients
• +4 more

Mary Beth Graham, MD, FIDSA, FACP is a Professor of Medicine with tenure at the Medical College of Wisconsin, where she serves as Associate Chief for the Division of Infectious Disease. She is also the Medical Director of Infection Prevention and Control at Froedtert Hospital and the Infection Prevention Program Director for the Medical College of Wisconsin. Dr. Graham is a Board Certified Internist and Infectious Disease specialist who joined the faculty at the Medical College of Wisconsin as an Assistant Professor of Medicine/Infectious Diseases in February 2002. Dr. Graham received her MD from Northwestern University Medical School in Chicago (1984), completed her Residency in Internal Medicine at the University of Washington Affiliated Hospitals in Seattle (1984-1987), and completed her Fellowship in Infectious Diseases at Washington University School of Medicine in St. Louis (1988-1991). Dr. Graham's clinical expertise includes HIV infection and associated complications, infections in immunocompromised individuals (including transplant recipients), influenza treatment and prevention, and the prevention of transmission of hospital-associated infections. She has an active outpatient clinical practice and also attends on the inpatient transplant and general infectious disease services. Her research has focused on infection control, particularly related to C. difficile, carbapenem-resistant organisms, and most recently on COVID-19 related complications including thrombosis and immune responses. Her publication record demonstrates a strong focus on clinical infectious disease research, with numerous studies on infections in immunocompromised hosts, antimicrobial resistance, and viral pathogenesis. Her work spans clinical trials, epidemiological studies, case reports, and immunological investigations, showing both clinical relevance and scientific rigor across multiple sub-specialties within infectious diseases. Best Doctors in America Top Doctor (Castle Connolly/Milwaukee Magazine) Best Teaching Physician at Froedtert Hospital by Department of Medicine residents (2013) MCW Outstanding Medical Student Teacher award (2015) Dr. Graham has demonstrated exceptional commitment to medical education, having received multiple teaching awards. As the Infectious Disease Fellowship Program Director, she plays a pivotal role in training the next generation of infectious disease specialists. Her administrative leadership in infection prevention and control reflects her significant contributions to hospital epidemiology and patient safety, with practical applications of her research directly impacting clinical practice and hospital policy. Dr. Graham maintains an active clinical practice with a focus on complex infectious disease cases, particularly in immunocompromised patients. Her dual expertise in clinical care and infection prevention makes her a key resource for managing challenging cases and developing institutional protocols for infection control.

Timothy A. YapView profile

Professor

• Cancer Therapeutics
• Immunotherapy
• DNA Damage Response (DDR)
• +3 more

Dr. Timothy A. Yap is a Medical Oncologist and Physician-Scientist at The University of Texas MD Anderson Cancer Center, holding the Ransom Horne, Jr. Endowed Professorship for Cancer Research. He serves as Vice President and Head of Clinical Development in the Therapeutics Discovery Division and is a Professor in the Department of Investigational Cancer Therapeutics (Phase I Program) and the Department of Thoracic/Head and Neck Medical Oncology. His research focuses on developing molecularly targeted agents and immunotherapies, particularly targeting the DNA damage response (DDR) and novel biomarker-driven approaches. He leads clinical trials for agents like ATR, PARP1, and YAP/TEAD inhibitors, and has expertise in immunotherapy combinations, including PD-1/PD-L1 and other checkpoint inhibitors. Education: BSc (First Class Honors) in Immunology and Infectious Diseases from Imperial College London, MBBS from Imperial College London, PhD in Molecular Pharmacology from The Institute of Cancer Research. He completed clinical training at the Royal Marsden Hospital and Oxford. Research Interests: First-in-human trials, combinatorial drug development, translational biomarker analysis, and precision medicine. His work spans DDR inhibitors, epigenetic targets (EZH2/BET), metabolic pathways (Glutaminase/OXPHOS), and immune-oncology therapies. Grants & Awards: Active grants include NIH/NCI R01, DOD grants, V Foundation Scholar grant, and Golfers against Cancer grant. He has received prestigious awards for clinical research and leadership. Affiliations: Editor of Cancer Discovery , Associate Editor of British Journal of Cancer , and active in global oncology committees (AACR, ASCO, ESMO). He mentors early-career researchers and chairs academic workshops.

André Bueno GamaView profile

Assistant Professor

• Plant Pathology
• Disease Epidemiology
• Sugarcane Diseases
• +2 more

André Bueno Gama is Assistant Professor in the Department of Plant Pathology and Crop Physiology at Louisiana State University's College of Agriculture. He specializes in applied and fundamental research on sugarcane diseases affecting Louisiana's agricultural industry. Education: PhD in Plant Pathology, University of Florida (2021) MSc in Plant Pathology, University of São Paulo (2017) BS in Agronomy, University of São Paulo (2015) Dr. Gama's research focuses on the etiology, epidemiology, and management of economically significant sugarcane diseases including red rot, smut, Sugarcane Yellow Leaf Virus, mosaic virus, and ratoon stunt disease. His program employs interdisciplinary approaches with breeders and entomologists to develop integrated disease management strategies. His recent publications (2008-2023) demonstrate expertise in disease management systems, fungicide efficacy, molecular diagnostics, and decision-support tools for crop protection. Research emphasizes practical applications for sugarcane, citrus, strawberry, and turfgrass production systems. Dr. Gama teaches PLHL 7083 (Epidemiology and Crop Loss Assessment), training graduate students in disease dynamics, prediction models, and management strategies. His extension program monitors disease outbreaks and delivers timely solutions to Louisiana growers.

Aileen KeatingView profile

Professor

• Reproductive Toxicology
• Environmental Health
• Animal Science
• +3 more

Dr. Aileen Keating is a Professor in the Department of Animal Science at Iowa State University, Ames, Iowa. Her research focuses on reproductive toxicology, particularly the effects of environmental chemicals (e.g., perfluorooctanoic acid, zearalenone) and stressors (e.g., heat stress, obesity) on ovarian and hepatic physiology in animal models. She investigates molecular mechanisms underlying ovotoxicity, DNA damage responses, and proteomic changes in mice and swine. Education: PhD in Biochemistry (National University of Ireland, Galway, 2003), MSc in Biomedical Sciences (University of Ulster, 1999), BSc in Microbiology (National University of Ireland, 1998). Research emphasizes interdisciplinary approaches to understand how toxicants and metabolic conditions impact reproductive health. Key areas include developmental origins of ovarian disorders, aryl hydrocarbon receptor-mediated toxicity of PCBs, and heat stress effects on porcine reproduction. Collaborations include studies on pelvic organ prolapse in sows and biomarker identification for postpartum dysgalactia syndrome. Her work integrates proteomics, transcriptomics, and genomic analyses, with publications addressing obesity-DNA damage interactions, glyphosate effects on oocytes, and molecular responses to endocrine disruptors. She leads studies on toxicant-induced folliculogenesis alterations and mitigation strategies via dietary or pharmacological interventions. Grants and collaborations focus on translational research bridging animal models and human health implications. Active in mentoring and graduate education, contributing to collaborative programs in reproduction science.

Krystle J. McLaughlinView profile

Associate Professor

• Protein X-ray Crystallography
• Biochemistry
• Biophysics
• +3 more

Krystle J. McLaughlin is an Associate Professor of Chemistry at Vassar College, where she has been since 2017. She earned a B.A. in Physics from Colgate University (2006) and a PhD in Biophysics from the University of Rochester (2011), followed by a postdoctoral fellowship in pedagogical training and research at the University of North Carolina at Chapel Hill’s SPIRE program. Her research focuses on biochemical and biophysical studies of microbial proteins, particularly antibiotic resistance mechanisms in pathogens like Staphylococcus and Salmonella , using protein x-ray crystallography and cryo-electron microscopy. She is an elected member of the US National Committee for Crystallography. Teaching responsibilities include Biochemistry (Chem 272), Biophysical Chemistry (Chem 326), and Protein Crystallography (Chem 295). McLaughlin’s lab emphasizes undergraduate research, with recent grants including a 2022 Cottrell Scholar Award ($100,000) supporting research and teaching development. She has balanced her career with motherhood, leveraging tenure-clock extensions and childcare arrangements during the pandemic. Her pandemic-era innovations include recorded lectures and iPad-based teaching tools to enhance accessibility. Her research articles span structural biology of bacterial enzymes, conjugative proteins, and gut microbiome enzymes. McLaughlin collaborates on initiatives to improve STEM education equity, including developing course-based research experiences (CUREs) and placement tests for incoming chemistry students.

Carlo Ferri MariniView profile

Assistant Professor

• Aerobic Exercise Testing
• Resistance Exercise Prescription
• Exercise Physiology
• +3 more

Dr. Carlo Ferri Marini is an Assistant Professor at the Department of Human Movement Sciences, University of Groningen and University Medical Center Groningen. He holds a PhD cum laude from the University of Urbino, with additional studies at Colorado Mesa University and University College Dublin. His research focuses on optimizing exercise testing and prescription in healthy and clinical populations, particularly in aerobic and resistance exercise physiology. He collaborates internationally and serves as an Academic Editor for BMC Sports Science, Medicine and Rehabilitation and PeerJ . Key areas of research include exercise intensity methods, lifestyle interventions for breast cancer survivors, and cardiometabolic health. Notable projects include the MOVIS clinical trial on exercise and nutrition programs for cancer survivors and the TRIPL-A trial for type 2 diabetes management. His work emphasizes improving the benefit-to-risk ratio of physical activity through evidence-based approaches. Dr. Marini’s recent publications explore topics such as pedaling cadence effects on metabolic responses, gut microbiota changes in breast cancer survivors, and the validity of exercise intensity metrics. He also investigates the role of exercise in mitigating tumorigenic activity and enhancing quality of life in clinical populations. Collaborations span institutions globally, reflecting his commitment to interdisciplinary research. His research has been featured in journals like Scientific Reports , European Journal of Sport Science , and Frontiers in Oncology . Dr. Marini is affiliated with the SMART Movements research group, advancing knowledge in movement sciences and health. His work bridges clinical and applied research, aiming to translate findings into practical guidelines for improving public health outcomes.

• Tuberculosis Pathogenesis
• Mycobacterium tuberculosis
• Cell Wall Physiology
• +3 more

Christopher M. Sassetti is a Professor in the Department of Microbiology at the University of Massachusetts Chan Medical School (UMass Chan Medical School) and T.H. Chan School of Medicine. His research focuses on the pathogenesis of Mycobacterium tuberculosis, specifically understanding how the bacterium adapts to host environments, acquires nutrients, regulates its cell wall physiology, and survives antibiotic treatment. He completed his BS in Biology at Santa Clara University and his PhD in Immunology at the University of California, San Francisco. Dr. Sassetti leads the Sassetti Lab, which employs genetic, biochemical, and systems biology approaches to study tuberculosis. His work has identified critical metabolic pathways and survival mechanisms in M. tuberculosis, including cholesterol utilization and cell wall synthesis regulation. He holds additional academic roles in the Morningside Graduate School of Biomedical Sciences, including the Immunology and Microbiology Program, MD/PhD Program, and Postbaccalaureate Research Education Program. Recent research highlights include studies on host immune responses to tuberculosis, antibiotic efficacy under infection conditions, and the role of genetic interactions in pathogen survival. His lab has discovered that host fatty acid metabolism and autophagy pathways play key roles in restricting bacterial growth. Dr. Sassetti has been recognized as a Damon Runyon Foundation Scholar and has contributed to high-impact publications in Immunity , Science , and Cell . Current projects include understanding nutrient acquisition in vivo, phosphosignaling regulation of cell wall synthesis, and metabolic mechanisms driving antibiotic tolerance. Collaborative efforts with institutions like the Morningside Graduate School and global networks drive translational research toward novel tuberculosis therapies and vaccines.

Elizabeth C ThompsonView profile

Assistant Professor

• Adolescent Mental Health
• Psychosis-Spectrum Disorders
• Early Intervention
• +4 more

Elizabeth C Thompson is Dean of Pembroke College and holds dual appointments as Assistant Professor of the Practice in Cognitive and Psychological Sciences and Assistant Professor of Psychiatry and Human Behavior (Research) at Brown University. She is a licensed psychologist in Rhode Island, with a Ph.D. in Clinical Psychology from the University of Maryland, Baltimore County, and postdoctoral training at Alpert Medical School and Brown University Health. Her research focuses on psychosis-spectrum disorders in adolescence, emphasizing risk factors, screening methods, and intervention strategies for mental health and safety risks. Dean, Pembroke College Assistant Professor of the Practice, Cognitive and Psychological Sciences Assistant Professor of Psychiatry and Human Behavior (Research) At Brown, Dr. Thompson operates within the Department of Cognitive and Psychological Sciences and the Department of Psychiatry and Human Behavior. She teaches clinical psychology courses and advises students pursuing psychology careers. Her clinical work centers on early psychosis through Bradley Hospital’s Stride Clinic, offering assessment and consultation services for Rhode Island youth and families. Her research includes pilot trials on family-oriented interventions for hospitalized adolescents with psychosis-spectrum symptoms and funded projects on sleep characteristics linked to psychosis-spectrum disorders, supported by the COBRE Center for Sleep and Circadian Rhythms. She collaborates extensively with researchers like Jennifer Wolff, Sarah Thomas, and Anthony Spirito. Dr. Thompson’s recent publications (2024–2019) span topics such as hallucinations and suicidal imagery, cannabis vaping effects, sleep disturbances, social media’s role in mental health, and trauma’s impact on psychosis. Her work often intersects with the Adolescent Mental Health Collaborative (AMHC) and utilizes interdisciplinary approaches, including actigraphy, biomarkers (e.g., interleukin-1 beta), and qualitative methods. She has secured NIH/NIMH, AFSP, and COBRE grants for studies like the LINC and Safety Net projects, reflecting her commitment to translating research into clinical practice. K23 MH119211 (NIH/NIMH): Treatment Engagement Protocol for Post-Discharge Psychosis Care YIG-1-167-19 (AFSP): Safety Planning for High-Risk Teens COBRE Center Grant: Sleep and Psychosis in Adolescents Her lab, SPARK Lab, partners with specialized clinics and emphasizes training opportunities in mental health research. She also contributes to policy discussions around early psychosis care quality and access, advocating for psychological expertise in healthcare synthesis. No scientific awards are explicitly mentioned, though her grant-funded research underscores her academic influence.

Helen GrovesView profile

Academic

• Respiratory Syncytial Virus (RSV)
• Paediatric Infectious Diseases
• Early-Life Immune Responses
• +5 more

Dr. Helen Groves is a Clinical Lecturer in Paediatric Infectious Diseases at Queen’s University Belfast’s School of Medicine, Dentistry and Biomedical Sciences, based at the Wellcome Wolfson Institute for Experimental Medicine. She completed postgraduate training in the UK Clinical Academic Training Program, including an Academic Clinical Lectureship at Queen’s University Belfast and a Wellcome Trust-funded PhD on early immune responses to respiratory syncytial virus (RSV). Her clinical training included a subspecialty program in the UK and a Clinical Fellowship at the Hospital for Sick Children in Toronto (2019–2021). Education: Helen Groves earned a Doctor of Philosophy (PhD) in 2018 from Queen’s University Belfast, supervised by Dr. U. F. Power and Dr. M. Shields. Her thesis, titled Elucidation of the roles of PTN and ISG15 in RSV cytopathogenesis: possible biomarkers of severe disease , explored RSV-driven immune mechanisms. She holds qualifications from the UK’s postgraduate Clinical Academic Training Program and subspecialty Paediatric Infectious Diseases training. Research Interests: Her work focuses on early-life respiratory viral infections, particularly RSV, aiming to understand immune responses and develop treatments. Key projects include leading the INHALER study (examining pandemic impacts on asthma/viral-wheeze development) and co-leading the PRECISE study (evaluating point-of-care testing for corticosteroid guidance in preschool wheeze). She is also a co-investigator in the pan-European CAR-CF trial, analyzing antibody responses in cystic fibrosis patients. Scientific Awards: Notable recognitions include: Clinical Academics in Training Annual Conference 2024 runner-up for post-doctoral plenary presentation Colonel Davis Research Scholarship (2017) First prize for oral presentations at the Annual Postgraduate Research Symposium (2017 and 2016) First prize at the BPAIIG Winter Meeting 2018 Advising & Grants: Helen has secured Wellcome Trust PhD funding and currently oversees major collaborative studies. Her work involves peer-review roles, including for the Pediatric Infectious Disease Journal , and editorial activities with the European Society for Paediatric Infectious Diseases. She actively participates in conferences and workshops, such as the Clinical Academics in Training Annual Conference 2024 and Health Data Research UK events. Labs & Teams: Based at Queen’s University Belfast’s Wellcome Wolfson Institute, she collaborates internationally in studies like the CAR-CF trial and INHALER/PRECISE cohort projects. Her network includes institutions in Canada, the US, and Europe, emphasizing global pediatric health research.

• Pancreatic Cancer
• Gastrointestinal Cancer
• Surgical Oncology
• +5 more

Dr. Andrew M. Lowy is a Professor of Surgery at the University of California San Diego School of Medicine, specializing in surgical oncology with a primary focus on pancreatic, liver, and gastrointestinal cancers. As a leading expert in pancreatic cancer treatment, he has pioneered the use of heated intraperitoneal chemotherapy (HIPEC) or 'chemo bath' for advanced abdominal cancers. Dr. Lowy serves on editorial boards of the Journal of Clinical Oncology and Annals of Surgical Oncology, and co-chairs the National Cancer Institute's Pancreatic Cancer Task Force. His research centers on pancreatic carcinogenesis and therapy, with particular emphasis on the RON receptor tyrosine kinase and its role as a potential therapeutic target. His laboratory develops models for testing novel therapeutics, focusing on translational applications for pancreatic cancer treatment. His work spans molecular biology, cancer signaling pathways, and innovative therapeutic approaches including targeted therapies and immunotherapies. Analysis of Dr. Lowy's recent publications reveals a strong emphasis on molecular mechanisms driving pancreatic cancer progression, with particular focus on tumor microenvironment interactions, metastasis mechanisms, and therapeutic resistance. His work increasingly incorporates advanced genomic and transcriptomic approaches while maintaining strong clinical relevance through participation in major cooperative group trials like SWOG. Dr. Lowy has secured significant research funding as Principal Investigator on multiple NIH grants, including several R01 awards from the National Cancer Institute, demonstrating the importance and impact of his research program. His extensive involvement in clinical trials reflects his commitment to translating laboratory findings into improved patient care. His laboratory and clinical team focus on advancing pancreatic cancer treatment through innovative surgical approaches, novel therapeutic targets, and biomarker development to guide personalized treatment strategies. The integration of basic science with clinical practice characterizes his comprehensive approach to improving outcomes for patients with gastrointestinal malignancies.

Alessia MelegaroView profile

Professor

• Demography
• Epidemiology
• Public Health Policy
• +7 more

Alessia Melegaro is a Full Professor of Demography and Social Statistics at Bocconi University's Department of Social and Political Sciences, and a Research Associate at the Dondena Centre for Research on Social Dynamics and Public Policy. She holds a Ph.D. in Quantitative Epidemiology from the University of Warwick, UK. Her work bridges demography, epidemiology, and public health, focusing on policy modeling, vaccine strategies, and healthcare economics. She directs Bocconi's Master in Data Science and Business Analytics and leads the Bocconi Covid Crisis Lab, a multidisciplinary initiative analyzing the pandemic's societal impact. As Principal Investigator of an ERC Consolidator Grant, she studies human behavior's role in infection spread. Her research explores optimal vaccination programs, demographic-behavioral interactions, and AI-driven health resource allocation. Notable contributions include analyzing social contact patterns during the pandemic, vaccine acceptance dynamics, and global health equity in vaccine distribution. Her work emphasizes interdisciplinary collaboration, combining mathematical models with real-world data to inform public health policies. Recent studies highlight behavioral interventions for mask-wearing and influenza vaccination uptake among corporate workers.

• Cancer Immunotherapy
• Gene Editing
• Immune Cell Engineering
• +3 more

Yueqi Zhang is a Molecular Research Assistant in the Department of Neuroscience at Yale University, affiliated with the Yale School of Medicine. Their research focuses on advancing therapeutic immune cell engineering, gene editing technologies, and cancer immunotherapy. Zhang holds an MD from Yale University (expected 2026) and a bachelor's degree from Central South University (2019). Key research areas include CRISPR-based genome editing systems (e.g., Cas12a and Cas13d), AAV-mediated delivery of genetic payloads, and metabolic modulation of CAR-T and CAR-NK cells. They have pioneered composite systems combining mRNA and viral vectors for immune cell engineering and developed in vivo CRISPR screens to identify therapeutic targets in tumor-infiltrating immune cells. Zhang's recent work (2023–2025) emphasizes multiplexed gene inhibition strategies, combinatorial immunotherapies, and translational platforms for clinical application. Their studies bridge molecular biology, systems immunology, and clinical oncology to address challenges in targeted therapy resistance and immune evasion mechanisms. Education: MD Candidate, Yale University School of Medicine (2026) Bachelor's Degree, Central South University (2019) Labs/Teams: Active in Yale's Molecular and Cellular Neuroscience programs and collaborates with teams developing AAV-based gene therapies and CRISPR engineering platforms.

Andrew Keane WoodsView profile

Professor

• Global Technology Regulation
• Data Sovereignty
• Cybersecurity
• +4 more

Andrew Keane Woods holds the Milton O. Riepe Professor of Law chair and directs the TechLaw program at the University of Arizona’s James E. Rogers College of Law. His research focuses on global technology regulation, including data sovereignty, platform governance, and international law. He has published in top journals like the Yale Law Journal and Stanford Law Review, and his work influences policy worldwide, cited by regulatory bodies and media outlets like The Economist and NPR. Education: A.B. from Brown University (magna cum laude, 2002), J.D. from Harvard Law School (cum laude, 2007), and Ph.D. in Politics from the University of Cambridge (Gates Scholar, 2012). Prior roles include visiting professorships at the University of Texas and University of Copenhagen, a Climenko Fellowship at Harvard Law School, and postdoctoral research at Stanford University. Research interests emphasize balancing innovation with legal frameworks, particularly in cybersecurity, cross-border data issues, and ethical AI. His recent work explores social contracts in digital contexts and regulatory responses to AI-driven challenges like shallow fakes. Key publications address data localization, platform liability, and the evolving role of tech firms in global governance. Awards include the Fulbright Schuman Innovation Award (2023) and recognition as a Gates Scholar. His contributions extend beyond academia: he has testified before Congress, advised regulatory agencies, and writes for outlets like the New York Times and Lawfare. Advising and grants highlight collaborative research on emerging technologies and their legal implications. He leads the TechLaw program, fostering interdisciplinary dialogue on law, technology, and policy. Ongoing work focuses on AI ethics in healthcare and the intersection of international law with digital sovereignty.

• Healthcare Quality Improvement
• Clinical Decision Support Systems
• Diabetes Management
• +3 more

Jason Fish is a Clinical Professor in General Internal Medicine and Chief Executive Officer of Yale Health at Yale School of Medicine. He holds a MD from Weill Cornell Medical College, an MS in Health Services Research from UCLA, and executive education in healthcare leadership. His research focuses on healthcare quality improvement methodologies such as Lean Six Sigma, clinical decision support systems, and process optimization in chronic disease management. Notable projects include improving depression screening in oncology, diabetes control in endocrine clinics, and rheumatoid arthritis treatment protocols. He has contributed to advancing electronic health record systems and preventive care metrics. Education: MD (Weill Cornell), MS Health Services Research (UCLA) Roles: Chief Executive Officer (Yale Health), Clinical Scholar (Robert Wood Johnson Program) Research emphasizes translating quality improvement strategies into clinical practice, with a focus on diabetes, rheumatology, and mental health integration. Recent work highlights interdisciplinary applications of Lean Six Sigma to enhance care outcomes and reduce disparities. Awards and recognitions are not explicitly listed in the provided text. Advising and grant activities are not detailed here, though his leadership roles suggest involvement in institutional initiatives. Active in Yale Health’s operational and strategic leadership, contributing to the School of Medicine’s mission through clinical and administrative expertise.

• Hepatobiliary Surgery
• Cancer Therapy
• Magnetic Surgery
• +4 more

Lyu Yi is a distinguished academic and clinician serving as Professor in the Department of Hepatobiliary Surgery at Xi'an Jiaotong University. He currently holds leadership roles including Vice President of Xi'an Jiaotong University, Director of The First Affiliated Hospital, and Director of the National Local Joint Engineering Research Center for Precision Surgery & Regenerative Medicine. His career spans over three decades in hepatobiliary surgery, transplantation medicine, and biomedical innovation. Education: Bachelor's in Clinical Medicine (1984, Xi'an Medical College) Master's (1990) and PhD (1995) in General Surgery from Xi'an Medical College Postdoctoral training in Surgery at Nippon Medical School Hospital, Tokyo (1998–2000) Research focuses on magnetic surgery innovations, liver transplantation, cancer therapy, and regenerative medicine. Key contributions include magnetic anastomosis devices and consensus guidelines for magnetic surgical techniques. Awards include the First Prize of Chinese Medical Technology Award (2018) and National Teaching Achievement Award (2023). Editor-in-Chief of Magnetic Medicine and holds leadership roles in surgical societies like the American College of Surgeons. Grants include National Key Research Programs (e.g., 2023YFF0713700, ¥120M) and NSFC projects. Over 30 patents filed, including magnetic vascular anastomosis systems. Active in surgical education and training device development such as the 'Magnetic Spiderman' surgical simulator.